ArticleAnnals of the rheumatic diseases2010
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.
Article in Annals of the rheumatic diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Cited by 412 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area
Prospective Randomized, Double-blind Controlled Clinical Study of N-acetylcysteine for Treatment of Dryness Symptoms Due to Primary Sjogren's Syndrome
Efficacy, Immunogenicity and Safety of Recombinant Vaccine Against Herpes Zoster (RZV or SHINGRIX®) in Patients With Autoimmune Rheumatic Diseases
Treatment of vaginal dryness in sjögren's disease with co2-laser versus topical promestriene: a prospective randomized study
Who cites it
412 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Recommendations on neurologic, cognitive, and psychiatric manifestations in patients with Sjögren's disease by the Brazilian Society of Rheumatology.Advances in rheumatology (London, England) · 2025Guideline
- Recommendations on cutaneous and hematological manifestations of Sjögren's disease by the Brazilian Society of Rheumatology.Advances in rheumatology (London, England) · 2024Guideline
- Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome.Annals of the rheumatic diseases · 2022Pooled it
- CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.Nature medicine · 2024Trial
- Development and validation of a nomogram for predicting fatigue in patients with primary Sjögren's syndrome.Clinical rheumatology · 2024Trial
- A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome.Rheumatology (Oxford, England) · 2023Trial
- Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Diagnostic value of delayed-phase 99mTc-HSA scintigraphy and treatment outcomes in connective tissue disease-associated protein-losing enteropathy.Clinical rheumatology · 2026Article
- Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real-World US Survey.ACR open rheumatology · 2026Article
- Article
- Characteristic clinical and immunologic features of Sjögren's disease patients presenting with major salivary gland swelling at diagnosis.Clinical rheumatology · 2026Article
- NETs mediate neuropathic pain in PSS-PN by participating in inflammatory injury to the vasa nervorum.Clinical rheumatology · 2026Article
- Serum growth differentiation factor 15 as a candidate biomarker associated with interstitial lung disease in primary Sjögren's syndrome: a clinical cross-sectional study.Clinical rheumatology · 2026Article
- [Practical management of Sjögren's disease in the era of new treatment options : Current value of available outcome parameters].Zeitschrift fur Rheumatologie · 2026Article
- [Epidemiology and manifestations of Sjögren's disease].Zeitschrift fur Rheumatologie · 2026Article
- Clinical characteristics and prognosis of primary Sjögren's disease patients with hypocomplementemia: reduced C3 is independently associated with new-onset peripheral cytopenias.Clinical rheumatology · 2026Article
- The Clinical Utility of Labial Gland Biopsy in Patients With Suspected Neuro-Sjögren.Immunity, inflammation and disease · 2026Article
- Medication adherence is associated with the necessity-concern differential in newly diagnosed primary Sjögren disease: a prospective observational cohort study.Rheumatology international · 2026Observational
- Salivary Dysfunction in Primary and Secondary Sjögren's Syndrome: Functional Assessment and the Exploratory Role of Salivary Microcrystallization.Dentistry journal · 2026Article
- Minor salivary gland biopsies in childhood-onset Sjögren's disease show greater inflammation and more frequent fibrotic changes than in adult-onset Sjögren's disease.Arthritis research & therapy · 2026Article
352 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop a disease activity index for patients with primary Sjögren's syndrome (SS): the European League Against Rheumatism (EULAR) Sjögren's syndrome disease activity index (ESSDAI).
methodsThirty-nine SS experts participated in an international collaboration, promoted by EULAR, to develop the ESSDAI. Experts identified 12 organ-specific 'domains' contributing to disease activity. For each domain, features of disease activity were classified in three or four levels according to their severity. Data abstracted from 96 patients with systemic complications of primary SS were used to generate 702 realistic vignettes for which all possible systemic complications were represented. Using the 0-10 physician global assessment (PhGA) scale, each expert scored the disease activity of five patient profiles and 20 realistic vignettes. Multiple regression modelling, with PhGA used as the dependent variable, was used to estimate the weight of each domain.
resultsAll 12 domains were significantly associated with disease activity in the multivariate model, domain weights ranged from 1 to 6. The ESSDAI scores varied from 2 to 47 and were significantly correlated with PhGA for both real patient profiles and realistic vignettes (r=0.61 and r=0.58, respectively, p<0.001). Compared with 57 (59.4%) of the real patient profiles, 468 (66.7%) of the realistic vignettes were considered likely or very likely to be true.
conclusionsThe ESSDAI is a clinical index designed to measure disease activity in patients with primary SS. Once validated, such a standardised evaluation of primary SS should facilitate clinical research and be helpful as an outcome measure in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.